Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial

Lei Wu, Liangliang Gu, Weihao Fan, Min Wei, Tingjun Dai, Xiaoling Li, Lianchen Xiao, Bin Li, Dai-Shi Tian, Ruisheng Duan, Xiaofeng Li, Yuming Xu, Huaxing Meng, Ting Chen, Feng Gao, Feipeng Zhai, Juan Feng, Huan Yang, Runxiu Zhu, Cun-Jin Zhang, Qiang Meng, Bingmei Deng, Zhaoyou Meng, Feng Qiu, Hongyu Zhou, Wei Qiu, Qing Zhang, Hong Liu, Zhe Wu, Zhe Wang, Li Meng, Zunbo Li, Weizhou Zang, Feng Xiang, Jinjin Liang, Sijun Liu, Xifang Liu, Junbin Chen, Feng Li, Dehui Huang, Unknown, Bin Li

Open source

DOI: 10.1038/s41591-026-04583-4
Published: 2026-08-10
Container: Nature Medicine
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04583-4,
  title = {Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial},
  author = {Lei Wu and Liangliang Gu and Weihao Fan and Min Wei and Tingjun Dai and Xiaoling Li and Lianchen Xiao and Bin Li and Dai-Shi Tian and Ruisheng Duan and Xiaofeng Li and Yuming Xu and Huaxing Meng and Ting Chen and Feng Gao and Feipeng Zhai and Juan Feng and Huan Yang and Runxiu Zhu and Cun-Jin Zhang and Qiang Meng and Bingmei Deng and Zhaoyou Meng and Feng Qiu and Hongyu Zhou and Wei Qiu and Qing Zhang and Hong Liu and Zhe Wu and Zhe Wang and Li Meng and Zunbo Li and Weizhou Zang and Feng Xiang and Jinjin Liang and Sijun Liu and Xifang Liu and Junbin Chen and Feng Li and Dehui Huang and Unknown and Bin Li},
  year = {2026},
  journal = {Nature Medicine},
  doi = {10.1038/s41591-026-04583-4},
  url = {https://doi.org/10.1038/s41591-026-04583-4}
}

RIS

TY  - JOUR
TI  - Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial
AU  - Lei Wu
AU  - Liangliang Gu
AU  - Weihao Fan
AU  - Min Wei
AU  - Tingjun Dai
AU  - Xiaoling Li
AU  - Lianchen Xiao
AU  - Bin Li
AU  - Dai-Shi Tian
AU  - Ruisheng Duan
AU  - Xiaofeng Li
AU  - Yuming Xu
AU  - Huaxing Meng
AU  - Ting Chen
AU  - Feng Gao
AU  - Feipeng Zhai
AU  - Juan Feng
AU  - Huan Yang
AU  - Runxiu Zhu
AU  - Cun-Jin Zhang
AU  - Qiang Meng
AU  - Bingmei Deng
AU  - Zhaoyou Meng
AU  - Feng Qiu
AU  - Hongyu Zhou
AU  - Wei Qiu
AU  - Qing Zhang
AU  - Hong Liu
AU  - Zhe Wu
AU  - Zhe Wang
AU  - Li Meng
AU  - Zunbo Li
AU  - Weizhou Zang
AU  - Feng Xiang
AU  - Jinjin Liang
AU  - Sijun Liu
AU  - Xifang Liu
AU  - Junbin Chen
AU  - Feng Li
AU  - Dehui Huang
AU  - Unknown
AU  - Bin Li
PY  - 2026
JO  - Nature Medicine
DO  - 10.1038/s41591-026-04583-4
UR  - https://doi.org/10.1038/s41591-026-04583-4
ER  -

APA

Wu, L., Gu, L., Fan, W., Wei, M., Dai, T., Li, X., Xiao, L., Li, B., Tian, D., Duan, R., Li, X., Xu, Y., Meng, H., Chen, T., Gao, F., Zhai, F., Feng, J., Yang, H., Zhu, R., Zhang, C., Meng, Q., Deng, B., Meng, Z., Qiu, F., Zhou, H., Qiu, W., Zhang, Q., Liu, H., Wu, Z., Wang, Z., Meng, L., Li, Z., Zang, W., Xiang, F., Liang, J., Liu, S., Liu, X., Chen, J., Li, F., Huang, D., Unknown, & Li, B. (2026). Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04583-4

Source records

crossref · retrieved 2026-09-27T14:16:22.240Z